Navigation Links
AMT's EGM Passes All Resolutions and Strengthens Supervisory Board With Joseph Feczko, Steven Holtzman and Francois Meyer
Date:9/20/2010

currently a member of the Board of Directors of the Foundation for the National Institutes of Health, Research!America, the International Longevity Center and the New York Academy of Medicine (all US). He is a member of the Board of Directors of the Accordia Global Health Foundation and the Technical Expert Committee for Trachoma on the International Trachoma Initiative of the Task Force for Global Health. He is also a member of the Governing Board of the Technology Strategy Board of the United Kingdom. He is currently Chairman of the Board of Directors of Cardoz Pharmaceuticals AB (Sweden), and a member of the Board of Directors of Keryx Biopharmaceuticals, Inc. (US). Dr. Feczko is board-certified in Internal Medicine and a specialist in infectious diseases. He has a B.Sc. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine.

Steven H. Holtzman

Steven Holtzman, Executive Chairman of Infinity Pharmaceuticals, Inc. (US), is a highly experienced biotech entrepreneur, who has founded and led a number of life sciences companies. He also has substantial experience in building collaborations with major pharmaceutical companies and licensing products. From 1996 to 2001, Mr. Holtzman served as a Presidential Appointee to the United States National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences.

Mr. Holtzman served as Chief Executive Officer 2006 to 2009 and President 2007 to 2008 of Infinity Pharmaceuticals. He was also a co-founder of Infinity Discovery, Inc. and served as its Chief Executive Officer and as Chair of its Board of Directors from inception in 2001 until the time of its merger with Infinity Pharmaceuticals' predecessor company in 2006. He also served as President of Infinity Discovery from 2001 to 2006. From 1994 to 2001, he served as Chief Business Officer of Millennium Pharmaceuticals, Inc.
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Clinical Laboratory Management Associations ThinkLab 10 Surpasses Attendance Goals
2. NACVSA Points out Perils of Polygraph: Killer Passes Polygraph, Innocent Man Fails, Killer Goes On To Kill Again
3. New Promega Maxwell 16 LEV Blood DNA Kit Surpasses Concentration Standards in Less Time
4. NACVSA: Killer of Five Teenagers Passes Polygraph
5. Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
6. MedTrust Online Surpasses 5,000 Registered Users and Adds Dr. Henry Friedman to Oncology Advisory Board
7. New Vision Device Passes Virtual Collision Test for People with Tunnel Vision
8. OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance
9. China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification
10. Eklin Medical Surpasses 1,000th RapidStudy(R) Digital Radiography System Installation Featuring Canon DR Technology
11. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... VANCOUVER , Dec. 22, 2014 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development of ... paper out of the University of Calgary in conjunction ... North Carolina, which further validates the company,s ongoing clinical ... the effects of pattern baldness. The paper ...
(Date:12/22/2014)... December 22, 2014 ITRA Global, one ... occupiers of commercial real estate, has further expanded its ... in Perth and Brisbane, Western Australia, reports Mylinda Vick, ... , ITRA Global / ACORPP (Australian Corporate Property ... consultancy company providing property services to a wide range ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... 7 Cyberonics, Inc. (Nasdaq: CYBX ) today ... Food and Drug Administration ("FDA") to amend the protocol of ... VNS TherapyTM.Based on a reassessment of the study power and ... data analysis originally specified in the study protocol, the company ...
... Calif., Jan. 7 Codexis, Inc. today announced,a licensing ... publicly-undisclosed generic product, using a proprietary Codexis,biocatalyst. Teva, ... a,leading producer of this generic product. The product ... the United States. , Under ...
... Corporation, a leading,developer of targeted, systemic RNA interference ... the final tranche of its Series B,financing. Astellas ... investor, Lilly Ventures, also participating. The addition ... to $21.4 million. Intradigm will,use Series B ...
Cached Biology Technology:Cyberonics Provides Business Update on Depression Clinical Trial 2Cyberonics Provides Business Update on Depression Clinical Trial 3Codexis, Teva in Licensing Agreement Final 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 3
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... -- CIE San Diego has launched an innovative trust ... that enhances care coordination among social service and care ... earned a second $1 million grant from the Alliance ... in community and; will be recognized as a "Live ... 4-6p. CIE San Diego today announced the ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... for Agricultural Research and Development, and the company FARMARABA ... produce Omega 3 using marine plant micro-organisms. The ultimate ... highly valued fatty acid, and then apply them at ... centre, which has proven experience in the biotechnology and ...
... Children living near toxic waste sites in ... Indonesia may experience higher blood lead levels, resulting in a ... retardation, according to a study presented today by Kevin Chatham-Stephens, ... Medicine at Mount Sinai, at the Pediatric Academic Societies (PAS) ...
... than two million people in the United States suffer ... abnormal nerve cell firing in the brain which often ... therapies reduce seizures in about two-thirds of patients, the ... therapy and those who take drugs can experience harmful ...
Cached Biology News:Neiker-Tecnalia and FARMARABA produce Omega 3 using marine plant micro-organisms 2Children living near toxic waste sites experience higher blood lead levels resulting in lower IQ 2
...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Biology Products: